$EVGN

Tarcic Gabi (Chief Development Officer) purchased 1,129 shares of Evogene Ltd. (EVGN) at $0.60 on 2026-06-04.

Evogene (EVGN) reported Q2 2026 earnings, highlighting strategic changes and financial results. The board addressed a demand from dissident shareholders to replace them, emphasizing their transformation into an AI-driven company and securing key drug development agreements. The company reduced headcount and cash burn, raised capital, and monetized assets. Management expressed confidence in their strategy and long-term value creation, while preparing to add new board members.

Evogene Ltd. reported a 62% year-over-year net loss improvement to $1.8M in Q2 2026, driven by reduced operating expenses. The company restructured, cutting headcount and lowering cash burn. It monetized non-core assets and upgraded its ChemPass AI platform. Management aims to transition to preclinical trials and expects revenue growth from partnerships and milestone payments. Geopolitical risks in Israel and the Middle East were highlighted. Candidate tickers: EVGN.

Evogene Ltd. (EVGN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Evogene Reports Second Quarter and First Half 2026 Financial Results · Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product d

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) said Chairman Nir Nimrodi will join its Aug. 18, 2026 quarterly results call to address a situation involving dissident shareholders. The company plans to share its perspective and discuss potential implications for Evogene and shareholders. The call is scheduled for 9:00 AM ET.

RECANATI LEON purchased 460,000 shares of Evogene Ltd. (EVGN) at $0.64 ($0.29M total) on 2026-08-11.

RECANATI LEON purchased 800,000 shares of Evogene Ltd. (EVGN) at $0.50 ($0.40M total) on 2026-08-04.

EverGen Infrastructure Corp. reported Q2 2026 RNG production of 54,675 GJ, up 3.6% from Q1 2026 and 10.9% from Q2 2025. The company also retained Red Cloud Securities as its sole market maker, paying a $5,000 monthly fee, replacing its prior arrangement. EverGen trades on TSXV: EVGN and OTCQB: EVGIF.

Evogene (Nasdaq/TASE: EVGN) and Tel Aviv University’s Blavatnik Center for Drug Discovery announced a joint initiative to accelerate AI-driven small-molecule drug discovery. The program will use Evogene’s ChemPass AI™ generative engine and BCDD experimental infrastructure in an integrated Design-Make-Test-Analyze workflow to support selected academic and entrepreneurial projects.

Evogene Ltd, an AI-focused biotech company, has garnered attention after securing new funding through a registered direct offering and private placement. This financing aims to support its AI-enabled biotechnology platforms and diverse subsidiary pipelines in human health, agriculture, and biomaterials. The company utilizes a Computational Predictive Biology (CPB) platform and a hybrid asset-light model, relying on partnerships for commercialization while focusing on discovery and early development through its subsidiaries like Biomica, Lavie Bio, AgPlenus, and Canonic.